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The use of a commercial kit for the monocyte-activation test (MAT) was evaluated for assessing pyrogenic 
contamination of hyperimmune sera . Three batches of sera, two pyrogen free and one pyrogenic, were 
tested. Endotoxin spike recover indicated that sample dilutions from 1/2 to 1/10 are suitable. Kit transport 
and storage conditions were also evaluated, proving that an adequate cold chain must be assured to achieve 
good results. Furthermore, the commercial MAT kit seemed suitable to replace the rabbit pyrogen test 
(RPT) for pyrogen testing of hyperimmune sera, although further tests are needed to a full validation.
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INTRODUCTION
Pyrogens can be roughly defined as substances, 
derived from microorganisms, that induce fever in animals 
(Hartung, 2015). Lipopolysaccharide (LPS), lipoteichoic 
acid LTA (Morath, Geyer, Hartung, 2001), exotoxins 
(Blackman, Woodland, 1995), muramyldipeptide 
(Nakatani et al., 2002) and peptidoglycan (Schleifer, 1975) 
are examples of pyrogens whose ubiquity is a threat to 
human health due to their stability (Schindler et al., 2006).
Whenever a pyrogenic substance enters in the 
bloodstream, it stimulates innate immunity leading to 
the secretion of fever-inducing cytokines . The most 
important are Interleukin-1β (IL-1β), Interleukin-6 (IL-6), 
Tumor Necrosis Factor-a (TNF-a) and Interferon (IFN-g), 
which act in the thermoregulatory center of the organism, 
mediating a rise in body temperature (Schindler et al., 
2006).
All parenteral products for human use must be 
pyrogen free and Quality Control assessing pyrogenic 
contamination is mandatory (Brazilian Phamacopoeia, 
2010). In the beginning of the 20th century, a pyrogen test 
in rabbits (Rabbitt Pyrogen Test – RPT) was developed 
and since then it has been used to ensure the safety of 
biologicals (Hasiwa et al., 2013). However RPT is not 
suitable for certain pharmaceutical products – such as radio 
or chemotherapeutics, analgesics, steroids, cytokines, 
dopamine and immunosuppressive agents (Greenhough, 
2016) – and, as are all animal tests, it is expensive, prone to 
errors and ethically questionable. The bacterial endotoxin 
test (BET) – also called Limulus Amebocyte Lysate test 
(LAL) – was developed later based on the observation that 
the hemolymph of horseshoe crabs clots in the presence of 
endotoxins (Hasiwa et al., 2013). Considering the variety 
of existing pyrogens, BET should only be used to replace 
RPT when the potential contaminants are endotoxins. 
Even though, several plasma fractions or plasma derived 
medicinal products may inherently contain constituents 
which interfere with different LAL testing methods 
(EMEA, 2007; Potu, Burra, Patil, 2011). It has also been 
demonstrated that in certain biopharmaceutical product 
formulations containing citrate, phosphate and polysorbate 
the endotoxins can be masked and not detected by BET 
(Bolden et al., 2014).
Due to the importance of reducing animal testing 
for the quality control of biologicals in light of the 3 R’s 
principle, alternatives to RPT were developed taking 
into account the fever induction mechanism of pyrogen-
induced cytokines. The monocyte activation test (MAT), 
for example, is based on the detection of IL-6 or IL-1b 
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induced in human blood monocytes or monocytic cell lines 
stimulated in vitro by pyrogens (detailed by Peterbauer et 
al., 1999; 2000). The test was validated in an international 
collaborative study (Schindler et al., 2006) and in 2010 the 
MAT was incorporated in the European Pharmacopoeia 
(European Pharmacopoeia, 2010).
The most important drawback for the MAT is the 
need to use human blood with viable monocytes whose 
half-life is less than 2 hours in vitro. In addition, according 
to Brazilian rules, donated blood is the property of the 
federal government intended only for transfusions or for 
the purification of blood fractions (Brasil, 2001), besides 
biosafety concerns. In order to overcome the limitations 
related to the use of fresh blood, a cryopreservation 
method was developed, where the blood could be used 
immediately after thawing (Schindler et al., 2006). 
Commercially, cryopreserved blood is readily available, 
simplifying the MAT standardization. The commercially 
available MAT kit uses cryopreserved human blood as 
a source of monocytes and the response to pyrogenic 
substances is determined by measurement of the induced 
Interleukin – 1β (IL-1β) by ELISA. 
Hyperimmune sera are an important class of 
biological products constituted of purified specific F(ab’)2 
fragments produced in immunized horse. Antivenom 
sera are used for the treatment snakebite envenomation – 
anticrotalus, for instance – or in the treatment of patients 
with diseases caused by microorganisms (bacteria or 
virus), using antisera such as antitetanus, antidiphtheria 
or antirabies. Contamination with microbial molecules 
and protein aggregates, due to high protein concentration, 
during the production process may be the reason for the 
pyrogenicity that cannot be detected by BET (Schindler 
et al., 2006). 
The US Interagency Coordinating Committee for 
the Validation of Alternative Test Methods (ICCVAM) 
declared that “MAT is suitable after a product-specific 
validation as a replacement for the Rabbit Pyrogen Test 
(RPT)” (ICCVAM, 2008). But it must be validated for each 
product matrix (Bolden et al., 2014), specially to prove 
that inherent components will not interfere, resulting in 
errors.
The aim of this work was to evaluate the use of this 
commercial MAT kit as part of an effort to replace RPT of 
hyperimmune sera produced by Instituto Butantan, taking 
into account standardization and ease of use in a routine 
testing environment. 
The study was based on LPS recovery and the 
capacity to detect pyrogenicity in a pyrogen positive 
sample (as previously determined by RPT). Blood 
cryopreservation and transport conditions were also tested 
in order to assess the kit’s viability considering a routine 
use in quality control.
MATERIAL AND METHODS
Study design
This study consists of the evaluation of test 
suitability to detect pyrogens in hyperimmune sera. At 
least three individual tests were performed with known 
samples to evaluate equivalence and accuracy (spiking 
the sample with standard endotoxin). The relationship 
between kit transport conditions and test validity was also 
evaluated considering the kit temperature sensitivity.
Samples
Three batches of hyperimmune sera were used 
in this study: one anticrotalus serum (ACS) and one 
antidiphtheria serum (ADS), both non-pyrogenic; and 
one antitetanus serum (ATS), positive for pyrogens as 
determined by RPT. All samples were kindly provided by 
the Division of Scientific Development and Production of 
Instituto Butantan.
Standards
LPS (E. coli O113:H10:K-endotoxin) standard 
BRP batch 5 supplied by EDQM (European Directorate 
for the Quali ty of Medicines and HealthCare – 
European Pharmacopoeia) and distributed by Merck 
was reconstituted with non-pyrogenic water and stored 
at -80 °C until use. Standard interleukin-1β used as 
positive control in ELISA was supplied by Merck. Unless 
otherwise stated, all reagents were used according to 
supplier instructions.
Rabbit Pyrogen Test – RPT
No animals were used in this study; the samples were 
tested in rabbits by the internal quality control of Instituto 
Butantan, in accordance with the Brazilian Pharmacopoeia 
recommendations for the routine lot release (Brazilian 
Pharmacopoeia, 2010).
PyroDetect System
The MAT system supplied by Merck consists of 
the PyroDetect Kit (ELISA kit to detect human IL-1 β), 
Cryoblood (cryopreserved human blood), standard IL-1 β 
(ELISA positive control) and Standard LPS. The detection 
Monocyte Activation Test (MAT) as a possibility of replacement for the rabbit pyrogen test in hyperimmune sera
Braz. J. Pharm. Sci. 2018;54(2):e17530 Page 3 / 6
system was used following the manufacturer instructions. 
The assay was performed in two steps. Briefly, incubation 
with blood (fresh or cryopreserved) and ELISA to detect 
induced IL-1 β . Samples and standard endotoxin were 
incubated with cryopreserved blood (16-20 h, 37 °C, 5% 
CO2) under sterile conditions. The mixtures were then 
transferred to ELISA microplates coated with monoclonal 
antibody anti-IL-1 β (2 h, room temperature – RT). After 
washing, horseradish peroxidase labeled anti-human 
IL-1 β was added (1 h, RT). The microplate was washed 
and enzyme substrate was added (20 min, RT). The 
reaction was stopped with H2SO4 and the absorbance was 
recorded at 450 nm (reference at 630 nm). Regression and 
linearity of the standard curves were evaluated by using 
Combistats 4.0.
Limit of detection (LOD – average absorbance of 
four independent negative control samples increased 
by 3-fold the standard deviation and interpolated in the 
standard curve) was calculated by using GraphPad Prism® 
5.01.
Endotoxin recovery testing
In order to evaluate endotoxin recovery rates, the 
samples of antisera were diluted 1/2, 1/4, 1/8 and 1/10 in 
RPMI (Roswell Park Memorial Institute) medium (part 
of the PyroDetect kit) and submitted to the MAT either 
diluted uncontaminated or contaminated with 0.5 EU/
mL of standard endotoxin. Through the standard curve, 
endotoxin recovery was calculated by using GraphPad 
Prism 5.01 software, considering the Asymmetric 
sigmoidal model. The endotoxin recovery test was 
performed 3 times for dilutions 1/2, 1/4 and 1/8, and 4 
times for dilution 1/10. The ANOVA test was used to 
compare experimental groups. Relative standard deviation 
(RSD% – 100 x ratio standard deviation/mean) was 
calculated for all data groups.
Cryoblood transport
Cryoblood is a cryopreserved standardized human 
blood preparation (certified pool of 8-10 donors). It must 
be transported and stored at temperatures lower than 80 °C 
as indicated in the product notice.
Maximum Valid Dilution (MVD) calculation
In order to define the maximum dilution at which 
pyrogens can still be detected, MVD was calculated in 
accordance with the formula defined in the European 
Pharmacopoeia (European Pharmacopoeia, 2010):
MVD = CLC x C/LOD
where: CLC = contaminant limit concentration; C= 
concentration of test solution; LOD = Limit of detection 
of the test: 0.25 EU/mL; Endotoxin limit concentration for 
parenteral drugs: 5 EU/kg/h (European Pharmacopoeia, 
2010); - Maximum dose for each serum is specified in the 
respective product notice or in the user’s recommendations 
publ ished by the  Nat ional  Author i ty,  namely: 
ACS - 200 mL/70 kg/24 h; ADS - 120 mL/70 kg/24 h; 
ATS - 20 mL/70 kg/24 h. 
RESULTS
Endotoxin standard curve
Endotoxin standard curves were prepared for five 
different cryoblood lots. The difference between these 
lots regarded the transport conditions. All kit lots were 
transported in dry ice, though through different routes. 
Some were transported under rigid temperature control 
while others were not monitored and transported under less 
rigid temperature conditions. Two curves were prepared 
for the transport at a rigidly controlled and monitored 
temperature (more than 90% of the time the temperature 
was lower than 70 °C), and three for the transport at no 
rigid temperature conditions (Figure 1), herein called 
unmonitored. When the Cryoblood is transported at 
unmonitored, hence unknown, conditions (although after 
its arrival in the laboratory it was stored at temperatures 
lower than -80 °C), the results were lower than expected 
(Figure 1). Calculated LOD ranged from 0.010 EU/mL 
(curve 5) to 0.423 EU/mL (curve 3) (Table I). However, 
curves 2 and 3 were considered invalid due to their 
highest LOD (above 0.250 EU/mL), hence they were not 
considered in further analyses. 
Endotoxin recovery
The diphtheria antiserum, the tetanus antiserum 
and the crotalus antiserum were tested to assess the 
endotoxin recovery rate. In order to establish the better 
sample dilution to test performance, meaning the one 
or those whose recovery is in the range 50-200% and 
the Relative standard variation (precision) is as low as 
possible, the endotoxin recovery rate was plotted against 
sample dilutions (Figure 2). Using ANOVA, no significant 
differences were observed among the dilutions (p>0.05). 
However, when the sample was tested pure undiluted, 
recovery was lower than with the diluted samples, outside 
of the limit range (50-200%). 
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MVD calculation for tested antisera
MVD depends on the type of antiserum, because 
concentrations and uses vary according to the treatment 
conditions. Calculated values of MVD were: ACS: 168; 
ADS: 280 and ATS: 1680 all of them above the dilutions 
used in this study.
Monocyte Activation Test (MAT) 
Using the valid standard endotoxin curves (Figure 1, 
Table I), the endotoxin recovery rate was calculated for 
ADS (diluted 1/8), ATS and ACS (diluted 1/10); all results 
were within the required range of 50-200%. As expected, 
the non-spiked ATS resulted positive for pyrogen, i.e., above 
the limit of detection of the standard curve (Table II).
DISCUSSION
The suitability of a MAT commercial kit for pyrogen 
testing in hyperimmune serum samples was evaluated. 
Three different samples, positive and negative for 
pyrogens, were tested using the kit; in our experimental 
conditions, the presence of pyrogens was easily and 
accurately verified. The lowest RSD values in the 
endotoxin recovery rates were observed when the samples 
were diluted 1/2 until 1/10 (Figure 2) and sample dilution 
did not interfere with the endotoxin detection. These 
dilutions were lower than the maximum dilution value 
(MDV) for each sample, avoiding false-negatives due to 
high dilution. The commercial MAT kit used following 
the manufacturer’s recommended conditions successfully 
detected pyrogenicity (in endotoxin equivalent units – 
EEU/mL) in the pyrogenic sample.
The MAT commercial kit is easy to use but as a 
bacterial endotoxin is used as for the standard curve, 
the results depend on its suitable handling. Well-trained 
technicians would not have any difficulty performing the 
test adequately.
Animal testing for quality control of biologicals is 
TABLE I - Regression and non-linearity p values calculated for endotoxin standard curves as validity criteria. Cut-off and Limit of 
detection (LOD) calculated for each test
Curve p for regression p for non-linearity Cut-off LOD (EU/mL) Validity
1 0.001 0.955 0.174 0.179 Valid
2 0.004 0.398 0.035 0.269 Invalid
3 0.018 0.980 0.087 0.423 Invalid
4 0.000 0.969 0.511 0.107 Valid
5 0.000 0.843 0.621 0.010 Valid
FIGURE 2 - Endotoxin recovery rate (%) of the undiluted 
antiserum, the diluted serum and the antiserum spiked with 
standard endotoxin (0.5 EU/mL). The recovery rate was 
calculated by interpolation from the standard curve subtracting 
the endotoxin equivalent of the non-spiked sample. The numbers 
indicate the relative standard deviation for each dilution. There 
were no statistically significant differences among the groups.
FIGURE 1 - Endotoxin standard curves obtained with cryoblood 
transported under different conditions. Unmonitored (Curves 1, 
2 and 3) and monitored at a stable temperature (curves 4 and 5).
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living on borrowed time, depending only on the scientific 
community efforts to validate and implement alternatives. 
RPT is an important and mandatory safety test for some 
biologicals (Brazilian Pharmacopoeia, 2010), notably 
hyperimmune sera, but besides the ethical issues, rabbits 
are expensive animals to obtain and keep and for this 
test reuse is not recommended (Brazilian Phamacopoeia, 
2010). Established alternatives, such as BET, are mostly 
indicated for the control of water for injection, but is not 
suitable to warrant serum safety. In Brazil, unfortunately, 
an alternative to RPT is still not available. In order to reduce 
the total number of animals for batch control, an interesting 
approach might be the use of MAT for in-process control, 
leaving RPT just for the final product until the alternative 
test is fully validated and accepted by the national authority.
The purpose of this work was not to replace the 
method validation study, once only few parameters 
could be evaluated. Full validation should also include 
robustness and large sample number in order to check 
precision and accuracy (ICCVAM, 2008), in addition to 
spiking with other known pyrogens, such as lipotheicoic 
acid (Da Silva et al., 2016). However, this kind of study 
may become impracticable if kit transport and storage 
conditions are not properly monitored or controlled as 
demanded by the kit notice and as demonstrated in this 
study (Figure 1, Table I). The main advantage of using 
a commercial kit is the standardization of the reagents 
and, in this case, specifically cryopreserved blood. 
Since the use of fresh blood may be proove difficult for 
logistic or even legal issues (Brasil, 2001), commercial 
kits containing cryopreserved standardized blood are an 
interesting alternative, which could lead to the successful 
replacement of RPT. This available commercial blood 
consists of a standardized pool of 8-10 donors, certified, 
which means it might be an interesting advantage from 
thequality assurance point of view. Nevertheless, the 
drawback of this approach is the need for an appropriate 
cold chain maintenance to allow the use of cryopreserved 
blood, which could be an issue for developing countries. 
This became clear during this study. Kit transportation and 
storage must be carefully managed respecting reagents 
temperature sensitivity in order to avoid kit instability, 
ultimately leading to test invalidity (Figure 1). 
The test showed equivalence to RPT and detected 
pyrogens in the tested samples. Although a full validation 
study is still mandatory for the test to be implemented 
in a quality control routine, this study demonstrates that 
the MAT commercial kit is suitable for the detection of 
pyrogen in hyperimmune serum samples. 
ACKNOWLEDGMENTS
The authors would like to acknowledge Dr Celso 
Pereira Caricati for the kind and helpful support and DDTP 
for the antisera supply. Financial support by Fundação 
Butantan and CNPq (grant 403299/2012-8).
CONFLICT OF INTEREST
KL Buosi is application specialist at Merck SA, 
supplier of the Pyrodetect kit.
AUTHOR CONTRIBUTIONS
CLAU collected and analyzed data and wrote the 
manuscript; KLB and VFB wrote the manuscript; WQ 
idealized the project, collected and analyzed data and 
wrote the manuscript.
REFERENCES
Blackman MA, Woodland DL. In vivo effects of superantigens. 
Life Sci. 1995;57(19):1717-35.
Bolden JS, Claerbout ME, Miner MK, Murphy MA, Smith KR, 
Warburton RE. Evidence against a bacterial endotoxin masking 
effect in biologic drug products by limulus amebocyte lysate 
detection. PDA J Pharm Sci Technol. 2014;68(5):472-7.
TABLE II - Results for MAT performed with Cryoblood transported and stored under monitored and controlled conditions. The 
results for equivalent endotoxin and recovery rates are averages of quadruplicates. Samples were diluted 1/10 and the represented 
values are average of quadruplicates. ATS: tetanus antiserum; ADS: diphtheria antiserum; ACS: crotalus antiserum




ADS 1 0 0.4610 92
ATS 4 0.1380 0.7500 122
ACS 5 0 0.3532 71
ATS 0.2627 0.6189 71
C. L. A. Utescher, K. L. Buosi, V. F. Botosso, W. Quintilio
Braz. J. Pharm. Sci. 2018;54(2):e17530Page 6 / 6
Brasil. Lei nº 10.205, de 21 de março de 2001. [citado em 01 Dec 
2017]. Disponível em: http://www.planalto.gov.br/ccivil_03/
leis/leis_2001/l10205.htm
Brazilian Pharmacopoeia. 5 ed. Brasília: Anvisa; 2010. Part. 2.
da Silva CC, Presgrave OA, Hartung T, de Moraes AM, Delgado 
IF. Applicability of the Monocyte Activation Test (MAT) 
for hyperimmune sera in the routine of the quality control 
laboratory: Comparison with the Rabbit Pyrogen Test (RPT). 
Toxicol In Vitro. 2016;32:70-5. 
European Medicines Agency (EMEA), Replacement of rabbit 
pyrogen testing by an alternative test for plasma derived 
medicinal products. 2007. [citado em 01 DEC 2017]. Disponível 
em: http://www.ema.europa.eu/docs/en_GB/document_library/
Scientific_guideline/2009/09/WC500003599.pdf.
European Pharmacopeia. 7. ed. Monocyte activation test. 
General Method. Strasbourg: Council of Europe; 2010. Chap. 
2.6.30. 
Greenhough J. Life Cycle of an analytical method: a case study 




Hartung, T. The human blood pyrogen test – lessons learned in 
twenty years. ALTEX. 2015;32(2):79-100.
Hasiwa N, Daneshian M, Bruegger P, Fennrich S, Hochadel A, 
Hoffmann S, et al. Evidence for the detection of non-endotoxin 
pyrogens by the whole blood monocyte activation test. ALTEX. 
2013;30(2):169-208.
Interagency Coordinating Committee on the Validation 
of Alternative Methods. ICCVAM. ICCVAM test method 
evaluation report: validation status of five in vitro test 
methods proposed for assesssing potential pyrogenicity of 
pharmaceuticals and other products. 2008. [citado em 01 DEC 
2017]. Available from: https://ntp.niehs.nih.gov/iccvam/docs/
pyrogen/tmer/pyrotmer2008.pdf. 
Morath S, Geyer A, Hartung T. Structure-function relationship 
of cytokine induction by lipoteicoic acid from Staphylococcus 
aureus. J Exp Med. 2001;193(3):393-397.
Nakatani T, Tsuchida K, Sugimura K, Yoshimura R, Takemoto 
Y. Response of peripheral blood mononuclear cells in 
hemodialyzed patients against endotoxin and muramyldipeptide. 
Int J Mol Med. 2002;10(4):469-72.
Peterbauer A, Eperon S, Jungi TW, Werner ER, Werner-
Felmayer G. Interferon-gamma-primed monocytoid cell lines: 
optimizing their use for in vitro detection of bacterial pyrogens. 
J Immunol Methods. 2000;233(1-2):67-76.
Peterbauer A, Werner ER, Werner-Felmayer G. Further 
development of a cell culture model for the detection of bacterial 
pyrogens. ALTEX. 1999;16(1):3-8.
Potu A, Burra S, Patil AK. Monocyte activation test: a new 
pharmacoepial quality control test for pyrogens: a review. J Adv 
Pharm Sci. 2011;1(1):122-131.
Schindler S, Spreitzer I, Löschner B, Hoffmann S, Hennes 
K, Halder M, et al. International validation of pyrogen tests 
based on cryopreserved human primary blood cells. J Immunol 
Methods. 2006;316(1-2):42-51. 
Schleifer KH. Chemical structure of the peptidoglycan, 
its modifiability and relation to the biological activity. Z 
Immunitatsforsch Exp Klin Immunol. 1975;149(2-4):104-17.
Received for publication on 30th August 2017
Accepted for publication on 23th October 2017
This is an open-access article distributed under the terms of the Creative Commons Attribution License.
